Viibryd (VI-brid) will be marketed as a new "dual-acting" serotonergic antidepressant
July 2011
Viibryd (VI-brid) will be marketed as a new "dual-acting" serotonergic antidepressant.
Viibryd (vilazodone) inhibits serotonin reuptake like SSRIs...plus it's also a partial serotonin agonist.
The company hoped Viibryd would be more effective than SSRIs.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 300+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote